Answers are grounded in this paper and cite their sources.
After more than 50 years of platinum-based anticancer research only three compounds are in clinical use worldwide. The use of the well-known lead compound of this class of anticancer agents, cisplatin, is limited by its side effects and varying resistance mechanisms. Therefore, we report on platinum(ii) compounds with asparagusic acid derivatives as ligands which show interesting anticancer results on cisplatin resistant cell lines.
No takes yet. Share an insight, caveat, or question.
Hildebrandt et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: